Top

Published in:

Open Access 01-12-2014 | Review

The common inflammatory etiology of depression and cognitive impairment: a therapeutic target

Authors: David J Allison, David S Ditor

Published in: Journal of Neuroinflammation | Issue 1/2014

Abstract

Chronic inflammation has been shown to contribute to the development of a wide variety of disorders by means of a number of proposed mechanisms. Depression and cognitive impairment are two such disorders which may share a closely linked inflammatory etiology. The ability of inflammatory mediators to alter the activity of enzymes, from key metabolic pathways, may help explain the connection between these disorders. The chronic up-regulation of the kynurenine pathway results in an imbalance in critical neuroactive compounds involving the reduction of tryptophan and elevation of tryptophan metabolites. Such imbalances have established implications in both depression and cognitive impairment. This may implicate the immune system as a potential therapeutic target in the treatment of these disorders. The most common treatment modalities currently utilized, involve drug interventions which act on downstream targets. Such treatments help to reestablish protein balances, but fail to treat the inflammatory basis of the disorder. The use of anti-inflammatory interventions, such as regular exercise, may therefore, contribute to the effectiveness of current drug interventions in the treatment of both depression and cognitive impairment.

Available only for authorised users

Felger JC, Lotrich FE: Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013, 246: 199-229. 10.1016/j.neuroscience.2013.04.060.PubMedCentralCrossRefPubMed

Schiepers OJG, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005, 29: 201-217. 10.1016/j.pnpbp.2004.11.003.CrossRefPubMed

McAfoose J, Baune BT: Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev. 2009, 33: 355-366. 10.1016/j.neubiorev.2008.10.005.CrossRefPubMed

Gregor MF, Hotamisligil GS: Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011, 29: 415-445. 10.1146/annurev-immunol-031210-101322.CrossRefPubMed

Van Gaal LF, Mertens IL, De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature. 2006, 444: 875-880. 10.1038/nature05487.CrossRefPubMed

Festa A, D’Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000, 102: 42-47. 10.1161/01.CIR.102.1.42.CrossRefPubMed

Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M: Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia. 2002, 45: 151-10.1007/s125-002-8256-1.CrossRefPubMed

Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001, 21: 1876-1890. 10.1161/hq1201.100220.CrossRefPubMed

Maier SF, Goeler LE, Fleshner M, Watkins LR: The role of the vagus nerve in cytokine-to-brain communication. Ann N Y Acad Sci. 1998, 840: 289-300. 10.1111/j.1749-6632.1998.tb09569.x.CrossRefPubMed

10.

Watkins LR, Maier SF, Goehler LE: Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sci. 1995, 57: 1011-1026. 10.1016/0024-3205(95)02047-M.CrossRefPubMed

11.

Banks WA, Ortiz L, Plotkin SR, Kastin AJ: Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther. 1991, 259: 988-996.PubMed

12.

Chesnokova V, Melmed S, Angeles CL, Angeles L: Minireview: neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling. Molecules. 2014, 143: 1571-1574.

13.

Maes M, Lambrechts J, Bosmans E, Jacobs J, Suy E, Vandervorst C, de Jonckheere C, Minner B, Raus J: Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med. 1992, 22: 45-53. 10.1017/S0033291700032712.CrossRefPubMed

14.

Maes M: Major depression and activation of the inflammatory response system. Adv Exp Med Biol. 1999, 461: 25-46. 10.1007/978-0-585-37970-8_2.CrossRefPubMed

15.

Sluzewska A: Indicators of immune activation in depressed patients. Adv Exp Med Biol. 1999, 461: 59-73. 10.1007/978-0-585-37970-8_4.CrossRefPubMed

16.

Tobinick E: Tumour necrosis factor modulation for treatment of Alzheimer’s disease rationale and current evidence. CNS Drugs. 2009, 23: 713-725. 10.2165/11310810-000000000-00000.CrossRefPubMed

17.

Oxenkrug GF: Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann N Y Acad Sci. 2007, 1122: 35-49. 10.1196/annals.1403.003.CrossRefPubMed

18.

Gál EM, Sherman AD: L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res. 1980, 5: 223-239. 10.1007/BF00964611.CrossRefPubMed

19.

Oxenkrug GF: Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr J Psychiatry Relat Sci. 2010, 47: 56-63.PubMedCentralPubMed

20.

Kanai M, Nakamura T, Funakoshi H: Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: differential regulation in the mouse nervous system during development. Neurosci Res. 2009, 64: 111-117. 10.1016/j.neures.2009.02.004.CrossRefPubMed

21.

Dang Y, Dale WE, Brown OR: Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. Free Radic Biol Med. 2000, 28: 615-624. 10.1016/S0891-5849(99)00272-5.CrossRefPubMed

22.

Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR: Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991, 56: 2007-2017. 10.1111/j.1471-4159.1991.tb03460.x.CrossRefPubMed

23.

Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ: Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001, 78: 842-853. 10.1046/j.1471-4159.2001.00498.x.CrossRefPubMed

24.

Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA: Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol. 2000, 164: 3596-3599. 10.4049/jimmunol.164.7.3596.CrossRefPubMed

25.

Shirey KA, Jung J-Y, Maeder GS, Carlin DJM: Upregulation of IFN- γ receptor expression by proinflammatory cytokines influences IDO activation in epithelial cells. J Interf Cytokine Res. 2006, 26: 53-62. 10.1089/jir.2006.26.53.CrossRef

26.

Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L: Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. 2005, 310: 850-855. 10.1126/science.1117634.CrossRefPubMed

27.

Fallarino F, Grohmann U, Vacca C, Bianchi R: T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002, 9: 1069-1077. 10.1038/sj.cdd.4401073.CrossRefPubMed

28.

Owe-Young R, Webster NL, Mukhtar M, Pomerantz RJ, Smythe G, Walker D, Armati PJ, Crowe SM, Brew BJ: Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. J Neurochem. 2008, 105: 1346-1357. 10.1111/j.1471-4159.2008.05241.x.CrossRefPubMed

29.

Zhu C-B, Blakely RD, Hewlett WA: The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology. 2006, 31: 2121-2131.PubMed

30.

Morikawa O, Sakai N, Obara H, Saito N: Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol. 1998, 349: 317-324. 10.1016/S0014-2999(98)00187-3.CrossRefPubMed

31.

Delgado P: Serotonin function and the mechanism of antidepressant action by. Arch Gen Psychiatry. 1990, 47: 411-418. 10.1001/archpsyc.1990.01810170011002.CrossRefPubMed

32.

Culley WJ, Saunders RN, Mertz ET, Jolly DH: Effect of a tryptophan deficient diet on brain serotonin and plasma tryptophan level. Proc Soc Exp Biol Med. 1963, 113: 645-648. 10.3181/00379727-113-28451.CrossRefPubMed

33.

Gal EM, Drewes PA: Studies on the metabolism of 5-hydroxytryptamine (serotonin). II. Effect of tryptophan deficiency in rats. Proc Soc Exp Biol Med. 1962, 110: 368-371. 10.3181/00379727-110-27520.CrossRefPubMed

34.

Carpenter LL, Anderson GM, Pelton GH, Gudin JA, Kirwin PD, Price LH, Heninger GR, McDougle CJ: Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology. 1998, 19: 26-35. 10.1016/S0893-133X(97)00198-X.CrossRefPubMed

35.

Nishizawa S, Benkelfat C, Young SN, Leyton M, Mzengeza S, de Montigny C, Blier P, Diksic M: Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci. 1997, 94: 5308-5313. 10.1073/pnas.94.10.5308.PubMedCentralCrossRefPubMed

36.

Okuda S, Nishiyama N, Saito H, Katsuki H: 3-hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem. 2002, 70: 299-307. 10.1046/j.1471-4159.1998.70010299.x.CrossRef

37.

Braidy N, Grant R, Adams S, Guillemin GJ: Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J. 2010, 277: 368-382. 10.1111/j.1742-4658.2009.07487.x.CrossRefPubMed

38.

Stokes PE: The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Eur Neuropsychopharmacol. 1995, 5: 77-82. 10.1016/0924-977X(95)00039-R.CrossRefPubMed

39.

Pariante CM: Depression, stress and the adrenal axis. J Neuroendocrinol. 2003, 15: 811-812. 10.1046/j.1365-2826.2003.01058.x.CrossRefPubMed

40.

Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS: Hippocampal volume reduction in major depression. Am J Psychiatry. 2000, 157: 115-118. 10.1176/appi.ajp.157.7.1120.CrossRefPubMed

41.

Videbech P, Ravnkilde B: Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004, 161: 1957-1966. 10.1176/appi.ajp.161.11.1957.CrossRefPubMed

42.

Sheline YI: Untreated depression and Hippocampal volume loss. Am J Psychiatry. 2003, 160: 1516-1518. 10.1176/appi.ajp.160.8.1516.CrossRefPubMed

43.

Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein H-G, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, Bogerts B, Myint AM: Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?. J Neuroinflammation. 2011, 8: 94-10.1186/1742-2094-8-94.PubMedCentralCrossRefPubMed

44.

Carroll BJ, Curtis GC, Davies BM, Mendels J, Sugerman AA: Urinary free cortisol excretion in depression. Psychol Med. 1976, 6: 43-50. 10.1017/S0033291700007480.CrossRefPubMed

45.

Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R: Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002, 7: 468-473. 10.1038/sj.mp.4000995.CrossRefPubMed

46.

Lotrich FE: Major depression during interferon-alpha treatment: vulnerability and prevention. Dialogues Clin Neurosci. 2009, 11: 417-425.PubMedCentralPubMed

47.

Kessing LV: Cognitive impairment in the euthymic phase of affective disorder. Psychol Med. 1998, 28: 1027-1038. 10.1017/S0033291798006862.CrossRefPubMed

48.

Shah PJ, Ebmeier KP, Glabus MF, Goodwin GM: Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry. 1998, 172: 527-532. 10.1192/bjp.172.6.527.CrossRefPubMed

49.

Bender DA, McCreanor GM: Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem Soc Trans. 1985, 13: 441-443.CrossRefPubMed

50.

Alkondon M, Pereira EFR, Yu P, Arruda EZ, Almeida LEF, Guidetti P, Fawcett WP, Sapko MT, Randall WR, Schwarcz R, Tagle DA, Albuquerque EX: Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. J Neurosci. 2004, 24: 4635-4648. 10.1523/JNEUROSCI.5631-03.2004.CrossRefPubMed

51.

Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu H-Q, Schwarcz R: Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 2010, 35: 1734-1742.PubMedCentralPubMed

52.

Rassoulpour A, Wu H-Q, Ferre S, Schwarcz R: Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem. 2005, 93: 762-765. 10.1111/j.1471-4159.2005.03134.x.CrossRefPubMed

53.

Zmarowski A, Wu H-Q, Brooks JM, Potter MC, Pellicciari R, Schwarcz R, Bruno JP: Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci. 2009, 29: 529-538. 10.1111/j.1460-9568.2008.06594.x.CrossRefPubMed

54.

Wu H-Q, Pereira EFR, Bruno JP, Pellicciari R, Albuquerque EX, Schwarcz R: The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci. 2010, 40: 204-210. 10.1007/s12031-009-9235-2.PubMedCentralCrossRefPubMed

55.

Chess AC, Simoni MK, Alling TE, Bucci DJ: Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull. 2007, 33: 797-804. 10.1093/schbul/sbl033.PubMedCentralCrossRefPubMed

56.

Chess AC, Bucci DJ: Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res. 2006, 170: 326-332. 10.1016/j.bbr.2006.03.006.CrossRefPubMed

57.

Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW: Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999, 20: 106-118. 10.1016/S0893-133X(98)00067-0.CrossRefPubMed

58.

Gulaj E, Pawlak K, Bien B, Pawlak D: Kynurenine and its metabolites in Alzheimer’s disease patients. Adv Med Sci. 2010, 55: 204-211. 10.2478/v10039-010-0023-6.CrossRefPubMed

59.

Tobinick E, Gross H, Weinberger A, Cohen H: TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. MedGenMed. 2006, 8: 25.PubMedCentralPubMed

60.

Tobinick EL, Gross H: Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflammation. 2008, 5: 2-10.1186/1742-2094-5-2.PubMedCentralCrossRefPubMed

61.

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006, 163: 1905-1917. 10.1176/appi.ajp.163.11.1905.CrossRefPubMed

62.

Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000, 22: 370-379. 10.1016/S0893-133X(99)00134-7.CrossRefPubMed

63.

Fitzgerald P, O’Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med. 2006, 36: 37-43. 10.1017/S003329170500632X.CrossRefPubMed

64.

Nierenberg AA, Alpert JE: Depressive breakthrough. Psychiatr Clin North Am. 2000, 23: 731-742. 10.1016/S0193-953X(05)70194-5.CrossRefPubMed

65.

Coyle JT, Tsai G: The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl). 2004, 174: 32-38. 10.1007/s00213-003-1709-2.CrossRef

66.

Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR: Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008, 165: 1040-1047. 10.1176/appi.ajp.2008.07071135.PubMedCentralCrossRefPubMed

67.

Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP: Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry. 2008, 165: 82-89. 10.1176/appi.ajp.2007.07050724.CrossRefPubMed

68.

Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT: The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007, 164: 1593-1602. 10.1176/appi.ajp.2007.06081358.CrossRefPubMed

69.

Moriguchi S, Marszalec W, Zhao X, Yeh JZ, Narahashi T: Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther. 2004, 310: 933-942. 10.1124/jpet.104.067603.CrossRefPubMed

70.

Mathur N, Pedersen BK: Exercise as a Mean to Control Low-Grade Systemic Inflammation. 2008. 2008.

71.

Petersen AMW, Pedersen BK: The anti-inflammatory effect of exercise. J Appl Physiol. 2005, 98: 1154-1162. 10.1152/japplphysiol.00164.2004.CrossRefPubMed

72.

Ford ES: Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology. 2002, 13: 561-568. 10.1097/00001648-200209000-00012.CrossRefPubMed

73.

Albert MA, Glynn RJ, Ridker PM: Effect of physical activity on serum C-reactive protein. Am J Cardiol. 2004, 93: 221-225. 10.1016/j.amjcard.2003.09.046.CrossRefPubMed

74.

Abramson JL, Vaccarino V: Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med. 2002, 162: 1286-1292. 10.1001/archinte.162.11.1286.CrossRefPubMed

75.

Tomaszewski M, Charchar FJ, Przybycin M, Crawford L, Wallace AM, Gosek K, Lowe GD, Zukowska-Szczechowska E, Grzeszczak W, Sattar N, Dominiczak AF: Strikingly low circulating CRP concentrations in ultramarathon runners independent of markers of adiposity: how low can you go?. Arterioscler Thromb Vasc Biol. 2003, 23: 1640-1644. 10.1161/01.ATV.0000087036.75849.0B.CrossRefPubMed

76.

Fiers W: Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett. 1991, 285: 199-212. 10.1016/0014-5793(91)80803-B.CrossRefPubMed

77.

Mizuhara H, O’Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, Satoh S, Niwa M, Senoh H, Fujiwara H: T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med. 1994, 179: 1529-1537. 10.1084/jem.179.5.1529.CrossRefPubMed

78.

Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK: Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J. 2003, 17: 884-886.PubMed

79.

Keller C, Keller P, Giralt M, Hidalgo J, Pedersen BK: Exercise normalises overexpression of TNF-alpha in knockout mice. Biochem Biophys Res Commun. 2004, 321: 179-182. 10.1016/j.bbrc.2004.06.129.CrossRefPubMed

80.

Van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest. 1996, 97: 713-719. 10.1172/JCI118469.PubMedCentralCrossRefPubMed

81.

Kasapis C, Thompson PD: The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005, 45: 1563-1569. 10.1016/j.jacc.2004.12.077.CrossRefPubMed

82.

Weight LM, Alexander D, Jacobs P: Strenuous exercise: analogous to the acute-phase response?. Clin Sci (Lond). 1991, 81: 677-683.CrossRef

83.

Fallon KE: The acute phase response and exercise: the ultramarathon as prototype exercise. Clin J Sport Med. 2001, 11: 38-43. 10.1097/00042752-200101000-00007.CrossRefPubMed

84.

Morimoto Y, Zhang Q, Adachi K: Increased blood quinolinic acid after exercise in mice: implications for sensation of fatigue after exercise. J Heal Sci. 2011, 57: 367-371. 10.1248/jhs.57.367.CrossRef

85.

Ito Y, Saito K, Maruta K, Nakagami Y, Koike T, Oguri Y, Nagamura Y: Kynurenine concentration of serum was increased by exercise. Adv Exp Med Biol. 1999, 467: 717-722. 10.1007/978-1-4615-4709-9_93.CrossRefPubMed

86.

Di Luigi L, Botrè F, Sabatini S, Sansone M, Mazzarino M, Guidetti L, Baldari C, Lenzi A, Caporossi D, Romanelli F, Sgrò P: Acute effects of physical exercise and phosphodiesterase’s type 5 inhibition on serum 11 β-hydroxysteroid dehydrogenases related glucocorticoids metabolites: a pilot study.Endocrine 2014. in press..

87.

Salter M, Pogson CI: The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem J. 1985, 229: 499-504.PubMedCentralCrossRefPubMed

88.

Da Silva AE, de Aquino LV, Ruiz da Silva F, Lira FS, dos Santos RVT, Rosa JPP, Caperuto E, Tufik S, de Mello MT: Low-grade inflammation and spinal cord injury: exercise as therapy?. Mediators Inflamm. 2013, 2013: 971841.

89.

Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO: Exercise treatment for depression: efficacy and dose response. Am J Prev Med. 2005, 28: 1-8. 10.1016/j.amepre.2004.09.003.CrossRefPubMed

90.

Blumenthal JA, Babyak MA, Doraiswamy PM, Watkins L, Hoffman BM, Barbour KA, Herman S, Craighead WE, Brosse AL, Waugh R, Hinderliter A, Sherwood A: Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med., 69: 587-596. 10.1097/PSY.0b013e318148c19a.

91.

Rimer J, Dwan K, Lawlor DA, Greig CA, McMurdo M, Morley W, Mead GE: Exercise for depression. Cochrane database Syst Rev. 2012, 7: CD004366.PubMed

92.

Gligoroska JP, Manchevska S: The effect of physical activity on cognition - physiological mechanisms. Mater Sociomed. 2012, 24: 198-202. 10.5455/msm.2012.24.198-202.PubMedCentralCrossRefPubMed

Title: The common inflammatory etiology of depression and cognitive impairment: a therapeutic target
Authors: David J Allison
David S Ditor
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Neuroinflammation / Issue 1/2014
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-014-0151-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The common inflammatory etiology of depression and cognitive impairment: a therapeutic target

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Lithium ameliorates lipopolysaccharide-induced microglial activation via inhibition of toll-like receptor 4 expression by activating the PI3K/Akt/FoxO1 pathway

Dietary intervention rescues maternal obesity induced behavior deficits and neuroinflammation in offspring

Etanercept restores normal insulin signal transduction in β2-adrenergic receptor knockout mice

Inhibition of mammalian target of rapamycin improves neurobehavioral deficit and modulates immune response after intracerebral hemorrhage in rat

Synergistic white matter protection with acute-on-chronic endotoxin and subsequent asphyxia in preterm fetal sheep

Tauroursodeoxycholic acid reduces glial cell activation in an animal model of acute neuroinflammation